IRLAB A — IRLAB Therapeutics AB Income Statement
0.000.00%
Last trade - 00:00
- SEK676.88m
- SEK631.35m
- SEK5.68m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.026 | 0 | 208 | 61.1 | 5.68 |
Cost of Revenue | |||||
Gross Profit | -71.1 | -65.6 | 126 | -64.8 | -123 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 95.9 | 91.5 | 155 | 174 | 186 |
Operating Profit | -95.8 | -91.5 | 52.6 | -113 | -181 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -96.1 | -91.7 | 51.8 | -113 | -178 |
Provision for Income Taxes | |||||
Net Income After Taxes | -96.1 | -91.7 | 51.8 | -113 | -178 |
Net Income Before Extraordinary Items | |||||
Net Income | -96.1 | -91.7 | 51.8 | -113 | -178 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -96.1 | -91.7 | 51.8 | -113 | -178 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.33 | -1.92 | 1 | -2.19 | -3.43 |
Dividends per Share |